4771.Tw
The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
Business. The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
Analyst recommendations
6 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale of healthcare products and services.
The company maintains a market price of 199.5 TWD, with a market capitalization of 11,676,336,000 TWD. Its price-to-earnings ratio is 15.76, and the price-to-book ratio is 2.93, indicating a moderate valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 2.55, suggesting a reasonable ability to meet short-term obligations. However, the company's free cash flow is negative at -319,746,000 TWD, indicating that it is spending more on capital expenditures than it is generating in operating cash flow.
In terms of profitability, the company's return on equity is 18.59%, and its return on assets is 10.49%, both of which are strong indicators of efficient use of equity and assets. The operating income of 1,005,961,000 TWD and net income of 740,775,000 TWD reflect a healthy margin, although the gross profit of 1,425,991,000 TWD suggests that the company is managing its production costs effectively. The debt-to-equity ratio of 0.4 indicates a relatively low level of leverage, which is favorable for financial stability.
The company's revenue is concentrated in the healthcare services and equipment sector, with no specific geographic breakdown provided in the available data. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in healthcare demand. The company's growth trajectory is not explicitly detailed, but the negative free cash flow and capital expenditures of -1,214,371,000 TWD suggest that the company is investing in its operations, which could support future growth.
The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The negative net cash position after subtracting total debt is a key flag that may impact the company's ability to fund operations without external financing. Recent events, such as analyst estimates and price targets, suggest a generally positive outlook, with a mean price target of 240.00 TWD and a mean recommendation of 1.67, indicating a strong buy sentiment.
- The company has a strong return on equity and assets, indicating efficient use of capital.
- The company's liquidity position is moderate, with a current ratio of 2.55.
- The company is investing in its operations, as evidenced by the negative free cash flow and significant capital expenditures.
- The company faces a medium liquidity risk and a low dilution risk.
- Analysts have a generally positive outlook on the company, with a mean price target of 240.00 TWD.
- margin_outlook_rationale: The company's strong return on equity and assets suggests that it is maintaining healthy margins, which is a positive indicator for future profitability.
- rd_outlook_rationale: The company's investment in operations, as indicated by the capital expenditures, may support future research and development efforts.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 16,12 |
| Revenue | —no estimate | —no estimate | 4,3B TWD |
| Operating income | —no estimate | —no estimate | 1,3B TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 4771.TW Market data — financials · 2026-05-26
- Vizionfocus Inc Market data — analyst estimates · 2026-05-26